Clinical trial NCT00216125 (phase 3, status: completed)
Conditions: non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: cisplatin, etoposide, docetaxel
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologic or cytologic evidence of NSCLCUnresectable Stage IIIA (N2) OR Stage IIIB
             NSCLC.

          -  Unresectable Stage IIIA will be defined by the following criteria:

          -  N2 mediastinal lymph nodes must be multiple and/or bulky on CT scan such that in the
             opinion of the treating investigator, the patient is not a candidate for surgical
             resection

          -  N2 disease must be documented by biopsy, FDG-PET scan imaging, or by CT if nodes are >
             2 cm on CT scan

          -  Stage IIIb patients must have N3 or T4 status. N3 status must be documented by one of
             the following criteria:

          -  Contralateral (to the primary tumor) mediastinal lymph node, supraclavicular or
             scalene lymph nodes proven by biopsy, FDG-PET scan imaging, or by CT if nodes are > 2
             cm on CT scan.

          -  Patients with positive supraclavicular or scalene lymph nodes must not have disease
             extending up into the cervical region.

          -  All patients must have measurable or evaluable disease documented by CT, MRI, X-ray or
             physical exam within 28 days prior to study treatment.

          -  Negative pregnancy test

        Eligibility for Consolidation Therapy

          -  Following completion of induction chemoradiotherapy patients without local progression
             of disease or distant metastases will then be randomized to receive consolidation
             therapy with docetaxel or observation. Patients will be stratified and randomized
             based on stage IIIa vs IIIb disease at baseline, CR vs. non-CR following induction
             chemoradiation, and ECOG PS 0 or 1 vs. 2.

          -  Patients must have completed chemoradiotherapy per protocol and at least 4 weeks but
             no more than 8 weeks must have elapsed from the last day of induction therapy (the
             last day of radiation) to be eligible for randomization to consolidation with
             docetaxel or observation.

          -  Patients must have undergone re-staging tests according to the study calendar and
             determined to have no evidence of disease progression to be eligible for randomization
             to consolidation with docetaxel or observation.

          -  Patients must have an ANC > 1,500/mm3, platelet count > 100,000/ mm3, and hemoglobin >
             8 g/dl obtained within 14 days prior to registration for randomization to
             consolidation with docetaxel or observation.

          -  Patients must have adequate hepatic function as defined by a serum bilirubin <
             institutional upper limit of normal (ULN) and an AST and/or ALT < 2.5 X the upper
             limits of normal if alkaline phosphatase is < ULN, or alkaline phosphatase may be up
             to 4 X ULN if transaminases are < ULN within 14 days prior to registration for
             randomization to consolidation with docetaxel or observation.

        Exclusion Criteria:

          -  No prior chemotherapy or radiotherapy for lung cancer.

          -  No unintended weight loss > 5% body weight in the preceding 3 months prior to study
             treatment will not be eligible for this trial.

          -  No symptomatic peripheral neuropathy prior to entry onto the study. Peripheral
             neuropathy must be < Grade 1 to be eligible.

          -  No prior malignancy except for adequately treated basal cell or squamous cell skin
             cancer, in situ cervical cancer, or other cancer for which the patient has been
             disease-free for 5 years.

          -  No history of allergic reactions to drugs utilizing the vehicle polysorbate 80
             (docetaxel) and polysorbate 80 + polyethylene glycol (etoposide).

          -  If the patient has hearing loss at pre-study, performance of an audiogram is
             recommended (not mandatory) to document baseline hearing status in the event of
             possible further hearing loss due to cisplatin administration.

          -  No current breastfeeding